Publications by authors named "Irene Modesto"

Claim this Profile
M
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review.
David T Rubin, Walter Reinisch, Neeraj Narula, Daniel R Colucci, William Eastman, Irene Modesto

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program.
Marla C Dubinsky, Joseph Wu, Aoibhinn McDonnell, Krisztina Lazin, Martina Goetsch, Irene Modesto

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
Fernando Magro, Laurent Peyrin-Biroulet, Bruce E Sands, Silvio Danese, Vipul Jairath, Irene Modesto

Clin Gastroenterol Hepatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study.
Joana Torres, Geert R D'Haens, Miguel Regueiro, Genoile Santana, Julian Panés, Irene Modesto

Therap Adv Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis.
Séverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, Marla C Dubinsky, Miguel Regueiro, Irene Modesto

BMJ Open Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés, Irene Modesto

J Crohns Colitis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials.
Charlie W Lees, Joana Torres, Yvette Leung, Séverine Vermeire, Marc Fellmann, Irene Modesto

Therap Adv Gastroenterol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts.
David T Rubin, Joana Torres, Iris Dotan, Lan Terry Xu, Irene Modesto

Inflamm Bowel Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
Miguel Regueiro, Britta Siegmund, Andres J Yarur, Flavio Steinwurz, Krisztina B Gecse, Irene Modesto

J Crohns Colitis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panés, Stefan Schreiber, Irene Modesto

J Crohns Colitis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Stefan Schreiber, David T Rubin, Siew C Ng, Laurent Peyrin-Biroulet, Silvio Danese, Irene Modesto

J Crohns Colitis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Michael Chiorean, Marco Daperno, Charlie W Lees, Gianluca Bonfanti, Dimitrios Soudis, Irene Modesto

Adv Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
Mathieu Uzzan, Yoram Bouhnik, Maria Abreu, Harris A Ahmad, Shashi Adsul, Irene Modesto

J Crohns Colitis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto

Ann Rheum Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Gary R Lichtenstein, Benjamin L Cohen, Leonardo Salese, Irene Modesto, Wenjin Wang

Dig Dis Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
William J Sandborn, Geert R D'Haens, Bruce E Sands, Remo Panaccione, Siew C Ng, Irene Modesto

J Crohns Colitis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Kevin L Winthrop, Séverine Vermeire, Millie D Long, Julian Panés, Siew C Ng, Irene Modesto

Inflamm Bowel Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified Mayo score Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.
William J Sandborn, Bruce E Sands, Séverine Vermeire, Yvette Leung, Xiang Guo, Irene Modesto

Therap Adv Gastroenterol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Arnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, Jack A Cook, Irene Modesto

Clin Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
David T Rubin, Irene Modesto, Séverine Vermeire, Silvio Danese, Siew C Ng

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
William J Sandborn, Nervin Lawendy, Silvio Danese, Chinyu Su, Edward V Loftus, Irene Modesto

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.
Danielle Bargo, Theo Tritton, Joseph C Cappelleri, Marco DiBonaventura, Timothy W Smith, Irene Modesto

Inflamm Intest Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.
Charlie W Lees, J Jasper Deuring, Michael Chiorean, Marco Daperno, Gianluca Bonfanti, Irene Modesto

Therap Adv Gastroenterol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States.
Manasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, Xian Zhang, Gilaad G Kaplan, Irene Modesto

Clin Gastroenterol Hepatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review.
Marla C Dubinsky, Iris Dotan, David T Rubin, Mark Bernauer, Dipen Patel, Irene Modesto

Expert Rev Gastroenterol Hepatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis